Visual rehabilitation in keratoconus by altering corneal shape using the corneal crosslinking pen: initial results
Abstract
Background: A Phase I/II trial to evaluate the initial safety and performance of a novel corneal crosslinking device, the Corneal Crosslinking Pen in keratoconus patients. This was a prospective exploratory study with 12 months of follow up.
Methods: Twenty-one eyes of 21 patients aged 14-27 years and diagnosed with progressive keratoconus were enrolled and treated unilaterally. Corneal crosslinking (CXL) following an accelerated epi-off protocol with riboflavin was done using the Corneal Crosslinking Pen. Effectiveness endpoints included changes in astigmatism, maximum keratometry (KMax), and best corrected visual acuity (BCVA) compared to baseline. Safety included adverse events and changes in pachymetry, intraocular pressure (IOP), and endothelial cell count (ECC).
Results: Astigmatism was significantly reduced at 12 months by a mean (95% CI) of 0.56 (0.10, 1.03) D. KMax was also reduced by a mean of 0.63 D, but this was not significant. BCVA improved significantly by nearly four lines of vision (- 0.38; logMAR). No corneal thinning was observed; pachymetry, IOP and ECC all remained stable across 12 months. Adverse events were infrequent and mild.
Conclusion: These early results suggest that the Corneal Crosslinking Pen was safe and effective for CXL. Future studies will seek to confirm the large improvement seen for BCVA and elucidate a potential mechanism.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 21 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.